Terns Pharmaceuticals Inc
(STU:430)
€
5.6
0.05 (0.9%)
Market Cap: 470.26 Mil
Enterprise Value: 113.82 Mil
PE Ratio: 0
PB Ratio: 1.34
GF Score: 39/100 Terns Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023 / 06:00PM GMT
Release Date Price:
€11.56
(+0.52%)
Silvan Türkcan
JMP Securities LLC - Analyst
Okay, welcome back. My name is Silvan Türkcan. I cover precision medicines here at JMP Securities. It's my pleasure to host Erin Quirk --
Mark Vignola
Terns Pharmaceuticals, Inc. - CFO
Kerry Russell.
Silvan Türkcan
JMP Securities LLC - Analyst
Sorry, Kerry Russell and Mark Vignola from Terns Pharmaceuticals. Thank you so much for joining us today.
Mark Vignola
Terns Pharmaceuticals, Inc. - CFO
Thanks so much for having us. It's great to be here.
Kerry Russell
Terns Pharmaceuticals, Inc. - Chief Medical Officer, Metabolic
Thank you, Silvan.
Questions & Answers
Silvan Türkcan
JMP Securities LLC - Analyst
Terns is focused on developing, obviously, small molecules for -- with different mechanisms of action about a host of indications, and -- but some investors may still know you as the NASH company or a NASH company. So
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot